- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Multicenter, Open-label Extension Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
This study is looking at a new medicine called Fipaxalparant for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It's a second-stage trial to see how well it works and if it's safe over about a year.
For: Diffuse Cutaneous Systemic SclerosisPortugal · Greece · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis [HZNP-HZN-825-301]
This study is testing a new medicine, Fipaxalparant, for people with a serious skin condition called diffuse cutaneous systemic sclerosis. It aims to see if the medicine can improve lung function and other symptoms over about a year.
For: Diffuse Cutaneous Systemic SclerosisRomania · Austria · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2b Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety and Tolerability of HZN-825 in Subjects with Idiopathic Pulmonary Fibrosis
This study is testing a new medicine, Fipaxalparant, for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). Researchers want to see if it's safe and helps improve lung function over one to two years compared to a dummy pill.
For: Idiopathic Pulmonary FibrosisFrance · Poland · Netherlands